

**PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

## **LEPU Medical Technology (Beijing) Announces 2024 Annual Report**

Beijing, China, April 19, 2025- LEPU Medical Technology (Beijing) Co.,Ltd. (the “Company”) today announced its performance for the three months ended March 31, 2025:

During the reporting period, the Company achieved operating revenue of RMB 6,103.2691 million, a year-on-year decrease of 23.52%; net profit attributable to shareholders of the listed company of RMB 246.9377 million, a year-on-year decrease of 80.37%; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of RMB 221.4304 million, a year-on-year decrease of 80.28%. Net cash flow from operating activities was RMB 734.6439 million, a year-on-year decrease of 25.82%.

At the end of the reporting period, in accordance with the *Accounting Standards for Business Enterprises* and the *Listing Rules of the Shenzhen Stock Exchange*, the Company conducted a systematic impairment test on assets showing signs of impairment in 2024 and on all goodwill arising from investments. An independent professional valuation agency was engaged to assess specific companies. Most enterprises, particularly several large-scale ones, maintained sound operations with no impairment risks. Based on the Company's prudent assessment, total impairment losses on goodwill and other specific assets amounted to RMB 251.2809 million, impacting net profit attributable to shareholders of the listed company by RMB 216.6694 million. These primarily included: goodwill of RMB 89.1017 million from the acquisition of Suzhou Bosimei, with impairment provision of RMB 59.2822 million; goodwill of RMB 9.3428 million from the acquisition of Lepu Equipment, with impairment provision of RMB 3.6656 million; emergency product inventory impairment provision of RMB 135.7509 million after prudent evaluation; self-developed COVID-19 POCT intangible asset impairment provision of RMB 15.7897 million; and full impairment provisions totaling RMB 36.7924 million for discontinued R&D projects related to exenatide and nesiritide drug technologies.

At the end of the reporting period, the Company's total assets were RMB 24,573.1002 million, a decrease of 1.80% from the beginning of the period; net assets attributable to shareholders of the listed company were RMB 15,201.4214 million, a decrease of 4.85%; and weighted average ROE was 1.59%.

Excluding the impact of the above-mentioned goodwill and specific asset impairments, net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses would have been RMB 438.0998 million, a year-on-year decrease of 64.94% on a comparable basis.

The medical device segment accounted for the largest revenue share. During the reporting

period, it generated revenue of RMB 3,326.4913 million, down 9.47% YoY, including:

- Coronary Intervention: Revenue of RMB 1,621.8145 million, up 6.35% YoY;
- Structural Heart Disease: Revenue of RMB 469.3145 million, up 44.03% YoY;
- Surgical and Anesthesia: Revenue of RMB 541.3140 million, up 0.27% YoY;
- In Vitro Diagnostics: Revenue of RMB 332.5602 million, down 51.31% YoY.

Pharmaceutical segment revenue was RMB 1,757.7478 million, down 42.25% YoY, including: Formulations (Generics): Revenue of RMB 1,408.6698 million, down 46.50% YoY; APIs: Revenue of RMB 349.0780 million, down 14.99% YoY.

Medical services and health management segment reported revenue of RMB 1,019.0301 million, down 19.24% YoY. The Company provides cardiovascular healthcare services and management through specialized hospitals, diagnostic labs, and e-commerce platforms for medical supplies. Hefei Cardiovascular Hospital achieved rapid growth under new leadership, with revenue up 15.60% YoY.

## Financial Results

	2024	2023	Changes compared to previous year (%)
Operating revenue (RMB)	6,103,269,105.88	7,979,899,319.74	-23.52%
Net profit attributable to shareholders of the listed company (RMB)	246,937,715.50	1,258,200,337.67	-80.37%
Net profit attributable to shareholders of the listed company after deducting nonrecurring profits and losses (RMB)	221,430,404.42	1,123,116,336.93	-80.28%
Net cash flows from operating activities (RMB)	734,643,889.07	990,359,814.31	-25.82%
Basic earnings per share (RMB/share)	0.1336	0.6757	-80.23%
Diluted earnings per share (RMB/share)	0.1336	0.6757	-80.23%
Weighted average return on net assets	1.59%	8.23%	-6.64%
	End of 2024	End of 2023	Changes compared to the end of previous year
Total assets (RMB)	24,573,100,199.19	25,022,331,486.69	-1.80%
Net assets attributable to shareholders of the Company (RMB)	15,201,421,378.82	15,976,101,963.31	-4.85%

## **Full 2024 Annual report**

The full 2024 Annual Report is available on our website at <https://en.lepumedical.com/investors/>.

## **Contact information**

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

## **About LEPU**

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

## **Disclaimers**

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily

be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.